<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00637871</url>
  </required_header>
  <id_info>
    <org_study_id>7054IL/0044</org_study_id>
    <secondary_id>D6876C00044</secondary_id>
    <nct_id>NCT00637871</nct_id>
  </id_info>
  <brief_title>Casodex - Nolvadex Combination</brief_title>
  <official_title>Randomised, Double-blind, Placebo Controlled, Parallel-group, Multicentre Phase II Study to Assess Dose Response Relationship of Nolvadex (Oral Tablet) in Prophylactic Treatment of Gynaecomastia and Breast Pain Associated With CASODEX 150 mg (Oral Tablet), and to Assess the Tumour Controlâ€¦..</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <brief_summary>
    <textblock>
      This study looks at the relationship in the dose of nolvadex and the incidence of
      gynaecomastia and also Prostate Specific Antigen (PSA) inhibition when co-administered with
      Casodex. The aim of the study is to assess the optimal dose of nolvadex which will reduce the
      breast tissue adverse effects without reducing the efficacy of Casodex.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2002</start_date>
  <completion_date type="Actual">August 2005</completion_date>
  <primary_completion_date type="Actual">June 2005</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <secondary_outcome>
    <measure>To describe the extent of gynaecomastia and breast pain by treatment group</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To describe the relative change from baseline in sex hormones concentrations by treatment group</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To describe the pharmacokinetics of tamoxifen, N-desmethyltamoxifen and R-bicalutamide when nolvadex is co-administered at varying doses with CASODEX 150 mg once daily</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the tolerance of nolvadex when co-administered at varying doses with CASODEX 150 mg once daily</measure>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <condition>Gynaecomastia</condition>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Casodex</intervention_name>
    <description>150mg once daily</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tamoxifen</intervention_name>
    <arm_group_label>2</arm_group_label>
    <other_name>Nolvadex</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects with adenocarcinoma of the prostate gland but with no evidence of distant
             metastasis. The stage of disease should be T1-T4, any N, M0 confirmed histologically
             or cytologically

          -  Subjects in need of immediate hormonal therapy.

          -  PSA equal or above 4 ng/ml

        Exclusion Criteria:

          -  Presence of gynaecomastia and/or breast pain at screening visit

          -  Any previous endocrine therapy for prostate cancer other than neoadjuvant LHRH therapy
             prior to primary therapy of curative intent.

          -  Current use, or within the previous 6 months, of any medication known to have a high
             risk of causing gynaecomastia .

          -  Previous mastectomy or radiation to chest wall
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yves Fradet, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Quebec City</affiliation>
  </overall_official>
  <verification_date>January 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 12, 2008</study_first_submitted>
  <study_first_submitted_qc>March 17, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 18, 2008</study_first_posted>
  <last_update_submitted>January 21, 2011</last_update_submitted>
  <last_update_submitted_qc>January 21, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 24, 2011</last_update_posted>
  <keyword>Casodex</keyword>
  <keyword>bicalutamide</keyword>
  <keyword>Tamoxifen</keyword>
  <keyword>Gynaecomastia</keyword>
  <keyword>Prostate Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
    <mesh_term>Gynecomastia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tamoxifen</mesh_term>
    <mesh_term>Bicalutamide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

